The trial judged the tolerability, safety and efficacy of atogepant, at 60 mg once daily, compared to the highest-tolerated ...

Antibody-drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Now is a great time for income and value investors, especially in energy and pharma, with dividends and upside potential.

Johnson & Johnson (NYSE:JNJ) said that an advisory committee of the EU drug regulator, the European Medicines Agency (EMA), ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.